Biosimilars in Retinal Diseases: A Primer
Retinal disease management has witnessed remarkable advances with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), off-label bevacizumab (Avastin) and the latest molecule Brolucizumab i n the management of various retinal diseases such as diabetic macular...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-04-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/DLJO.DLJO_132_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Retinal disease management has witnessed remarkable advances with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), off-label bevacizumab (Avastin) and the latest molecule Brolucizumab i n the management of various retinal diseases such as diabetic macular oedema, neovascular age-related macular degeneration (AMD), and retinal vein occlusions. Patients usually need multiple and frequent dosing of these agents that cause increased financial burden and other unique challenges to the patients. Biosimilar molecules in future can potentially come in the mainstream clinical practice as a more cost-effective choice. It is important for clinicians to have a clear understanding about ophthalmic biosimilars before the industry brings these molecules to mainstream clinical use globally. This article provides an update on biosimilars and will help postgraduates to get a clear view about the various biosimilars that are already in use and those that are in pipeline. |
|---|---|
| ISSN: | 0972-0200 2454-2784 |